Baseline Elevated LDL Cholesterol
High LDL drives atherosclerotic risk before treatment.
- 160-190: Typical baseline LDL (mg/dL, untreated)
- <70: Target LDL (high risk) (mg/dL, guideline goal)
- ~200 M: Global statin users (worldwide estimate)
- #1: ASCVD risk driver (modifiable lipid factor)
Why LDL matters
LDL particles seed arterial plaque over years of exposure.
Who gets treated
Risk calculators combine LDL, age, and comorbidities.
Before therapy
Baseline labs set the reference point for dosing.
Statin Initiation & HMG-CoA Reductase
A starting dose blocks cholesterol synthesis in the liver.
- HMG-CoA: Target enzyme (reductase, rate-limiting step)
- 10-20: Typical starting dose (mg equivalent)
- ~2 wk: Onset of effect (to steady-state LDL drop)
- ↑: LDL receptor upregulation (compensatory hepatic response)
Enzyme blockade
Statins competitively inhibit the mevalonate pathway.
Hepatic response
Liver upregulates LDL receptors to compensate.
Starting low
Low starting doses limit early side-effect exposure.
Dose-Response Curve — The Rule of Six
Each dose doubling adds roughly six more points of LDL drop.
- ~6%: Rule of six (extra LDL cut per doubling)
- ~30→48%: 10mg → 80mg reduction (diminishing returns)
- Logarithmic: Curve shape (not linear with dose)
- 3: Dose doublings shown (10→20→40→80 mg)
Logarithmic gains
Big early gains shrink with every further dose step.
Clinical implication
Doubling dose rarely doubles benefit.
Practical ceiling
High doses buy little extra LDL-lowering.
Myopathy Risk Rises Disproportionately
Muscle risk accelerates with dose, especially with interacting drugs.
- CYP3A4: Myopathy mechanism (metabolism competition)
- Rare: Rhabdomyolysis (but dose- and drug-linked)
- Fibrates,: High-risk interactors (azoles, some antibiotics)
- Steepening: Risk curve shape (not linear with dose)
CYP3A4 competition
Interacting drugs raise statin blood levels sharply.
Dose amplification
High dose plus interaction compounds risk fastest.
Warning signs
Muscle pain, weakness, and dark urine need review.
Finding the Optimal Dose Window
Best dosing maximizes LDL benefit while limiting muscle risk.
- 20-40: Optimal window (no interaction) (mg equivalent)
- 11-16: Window with strong interaction (mg equivalent, narrowed)
- Lowest: Guiding principle (effective dose strategy)
- Med list: Key clinical check (review before uptitration)
Balancing act
Optimal dose trades marginal LDL gain for real risk.
Interaction check
Co-prescribed drugs shrink the safe dosing window.
Shared decision
Dose choice weighs patient risk and preference.